Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size has shown rapid expansion in recent years. This market is projected to expand from $8.41 billion in 2025 to $9.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.1%. The historical growth of this market can be linked to covid 19 vaccine programs, the rise of biotech startups, insufficient in-house manufacturing capabilities, an increase in contract manufacturing, and quick mrna platform validation.
The market for messenger ribonucleic acid (mRNA) vaccine contract development and manufacturing organizations (CDMO) is projected to experience swift expansion over the coming years, reaching $17.1 billion by 2030 with a compound annual growth rate (CAGR) of 15.3%. This anticipated growth is driven by factors such as the increasing development of mRNA cancer vaccines, the rise of personalized vaccines, an increase in CDMO collaborations, the need for quick large-scale manufacturing, and an expanding range of mRNA therapies in development. Key trends anticipated during this period encompass services for lipid nanoparticle formulation, accelerated mRNA process scale-up, outsourced integrated fill-finish solutions, adaptable modular vaccine manufacturing facilities, and comprehensive end-to-end mRNA development offerings.
Download A Free Sample Report For Comprehensive Market Insights:
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Expansion Drivers: What Is Shaping Future Growth?
The increasing occurrence of infectious and newly developing diseases is projected to drive the expansion of the mRNA vaccine CDMO market in the future. These diseases are conditions resulting from disease-causing microbes that either spread quickly or appear for the first time, influenced by aspects like environmental shifts, city growth, and enhanced global connections. Increased global movement, higher population concentrations, and interlinked supply networks have sped up the spread of pathogens, leading to more common, extensive, and challenging-to-manage disease outbreaks. mRNA vaccine CDMOs are essential in tackling these issues, facilitating the swift creation, large-scale production, and adaptable manufacturing of vaccines necessary to combat changing infectious dangers. Given that mRNA technologies demand specific manufacturing facilities and specialized knowledge, vaccine developers often partner with contract development and manufacturing organizations to speed up development schedules and ensure manufacturing capabilities are in place during outbreaks. As an example, in May 2024, data from the World Health Organization (WHO), the United Nations’ global health agency based in Switzerland, showed that by 30 April 2024, over 7.6 million dengue cases were reported worldwide to WHO, comprising 3.4 million confirmed cases, more than 16,000 severe cases, and upwards of 3,000 fatalities. This rise was notably significant in the Region of the Americas, with cases surpassing seven million by April 2024, which exceeded the 2023 annual total of 4.6 million cases. Consequently, the increasing occurrence of infectious and emerging diseases is fueling the expansion of the mRNA vaccine CDMO market.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Segment Breakdown: Which Categories Generate The Most Revenue?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types
2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up
2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process
3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing
4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization
5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging
6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading companies in the mRNA vaccine CDMO market are increasingly prioritizing innovative approaches, such as phase-appropriate GMP mRNA contract development and manufacturing services, to accelerate preclinical and IND-enabling development, while upholding regulatory-aligned quality standards and achieving shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production method designed to deliver high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the expenses and operational complexities associated with full GMP manufacturing. For instance, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service aimed at supporting preclinical and IND-enabling development. This service provides high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, reflecting the increasing demand for flexible, phase-appropriate CDMO solutions in the mRNA vaccine market.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Key Players And Strategic Industry Positioning
Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH
Access The Complete Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report:
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
